Glicerolo Ramini may be available in the countries listed below.
Ingredient matches for Glicerolo Ramini
Glycerol is reported as an ingredient of Glicerolo Ramini in the following countries:
- Italy
International Drug Name Search
Glicerolo Ramini may be available in the countries listed below.
Glycerol is reported as an ingredient of Glicerolo Ramini in the following countries:
International Drug Name Search
Amyline may be available in the countries listed below.
Glimepiride is reported as an ingredient of Amyline in the following countries:
International Drug Name Search
FOR TOPICAL USE ONLY (NOT FOR OPHTHALMIC USE)
Rx only
Rosadan™ (metronidazole) Topical Cream contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in an emollient cream consisting of emulsifying wax, sorbitol solution, glycerin, isopropyl palmitate, benzyl alcohol, lactic acid and/or sodium hydroxide to adjust pH, and purified water. Metronidazole is a member of the imidazole class of anti-bacterial agents and is classified therapeutically as an antiprotozoal and antibacterial agent. Chemically, metronidazole is 2-methyl-5-nitro-1H-imidazole-1-ethanol. The molecular formula is C6H9N3O3 and molecular weight is 171.16. Metronidazole is represented by the following structural formula:
The mechanisms by which metronidazole acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.
Rosadan™ (metronidazole) Topical Cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.
Rosadan™ (metronidazole) Topical Cream is contraindicated in individuals with a history of hypersensitivity to metronidazole, or other ingredients of the formulation.
Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.
This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.
Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.
Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.
There are no adequate and well-controlled studies with the use of Rosadan™ (metronidazole) Topical Cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.
After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established.
In controlled clinical trials, the total incidence of adverse reactions associated with the use of topical metronidazole cream was approximately 10%. Skin discomfort (burning and stinging) was the most frequently reported event followed by erythema, skin irritation, pruritus and worsening of rosacea. All individual events occurred in less than 3% of patients.
The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.
Apply and rub in a thin layer of Rosadan™ (metronidazole) Topical Cream twice daily, morning and evening, to entire affected areas after washing.
Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of Rosadan™ (metronidazole) Topical Cream.
Rosadan™ (metronidazole) Topical Cream, 0.75% is supplied in a 45 g tube - NDC 43538-180-45.
Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Manufactured for:
MEDIMETRIKS
PHARMACEUTICALS, INC.
363 Route 46 West
Fairfield, NJ 07004-2402 USA
www.medimetriks.com
Manufactured by:
G&W Laboratories, Inc.
South Plainfield, NJ 07080
IP019
8-0633MDM1
Issued 02/11
MEDIMETRIKS
PHARMACEUTICALS, INC.
NDC 43538-180-45
RX Only
Rosadan™
Metronidazole Topical Cream, 0.75%
NET WT 45 g
NDC 43538-181-45
RX Only
Rosadan™
Metronidazole Topical Cream, 0.75%
CREAM KIT
CONTENTS:
1-Rosadan™ Metronidazole Topical Cream, 0.75% Tube (Net wt. 45 g)
1-Rehyla™ Wash Moisturizing Daily Wash Bottle (16 fl. oz.)
MEDIMETRIKS
PHARMACEUTICALS, INC.
ROSADAN metronidazole cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
ANDA | ANDA077549 | 08/30/2011 |
ROSADAN metronidazole cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
ANDA | ANDA077549 | 08/30/2011 |
Labeler - Medimetriks Pharmaceuticals, Inc. (019903816) |
Establishment | |||
Name | Address | ID/FEI | Operations |
G&W Laboratories | 001271188 | MANUFACTURE |
Epilat may be available in the countries listed below.
Nifedipine is reported as an ingredient of Epilat in the following countries:
International Drug Name Search
Lizpion may be available in the countries listed below.
Lincomycin hydrochloride monohydrate (a derivative of Lincomycin) is reported as an ingredient of Lizpion in the following countries:
International Drug Name Search
Nifedicor may be available in the countries listed below.
Nifedipine is reported as an ingredient of Nifedicor in the following countries:
International Drug Name Search
Losargamma may be available in the countries listed below.
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losargamma in the following countries:
International Drug Name Search